@article{ATM10412,
author = {Christoforos Kosmidis and Konstantinos Sapalidis and Efstathios Kotidis and Nikolaos Mixalopoulos and Paul Zarogoulidis and Drosos Tsavlis and Sofia Baka and Yan-Gao Man and John Kanellos},
title = {Pancreatic cancer from bench to bedside: molecular pathways and treatment options},
journal = {Annals of Translational Medicine},
volume = {4},
number = {9},
year = {2016},
keywords = {},
abstract = {In the last forty years the pancreatic cancer treatment has made advances, however; still novel drugs are needed. It is known that the five year survival rate remains around 5%. The best treatment option still remains surgery, if patients are diagnosed early. In the last decade the biology of pancreatic cancer has been vastly explored and novel agents such as; tyrosine kinase agents, or vaccines have been added as a treatment perspective. The big challenge is now to translate this knowledge in better outcomes for patients. In this current review we will present information from pancreatic cancer diagnosis to molecular pathways and treatment options; current and future.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/10412}
}